89226-50-6
Chemical Structure
Manidipine
- CAS. Nr.: 89226-50-6
- Formula:C35H38N4O6
- Molecular Weight:610.70
IUPAC Name: 3-(2-(4-benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
InChIKey: ANEBWFXPVPTEET-UHFFFAOYSA-N
SMILES: O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCN3CCN(C(C4=CC=CC=C4)C5=CC=CC=C5)CC3
Biological Activity: Manidipine is an orally active calcium channel antagonist. Manidipine regulates the expression of cytokines (IL-1β, IL-6). Manidipine has a hypotensive effect. Manidipine can be used in the study of cardiovascular diseases (such as hypertension, myocardial ischemia-reperfusion injury, ventricular hypertrophy), kidney diseases (such as glomerular diseases), and epilepsy[1][2][3][4][5][6][7][8].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Manidipine | 99.92% | Manidipine is an orally active calcium channel antagonist. Manidipine regulates the expression of cytokines (IL-1β, IL-6). Manidipine has a hypotensive effect. Manidipine can be used in the study of cardiovascular diseases (such as hypertension, myocardial ischemia-reperfusion injury, ventricular hypertrophy), kidney diseases (such as glomerular diseases), and epilepsy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Manidipine (Standard) | ≥98% | Manidipine (Standard) is the analytical standard of Manidipine. This product is intended for research and analytical applications. Manidipine is an orally active calcium channel antagonist. Manidipine regulates the expression of cytokines (IL-1β, IL-6). Manidipine has a hypotensive effect. Manidipine can be used in the study of cardiovascular diseases (such as hypertension, myocardial ischemia-reperfusion injury, ventricular hypertrophy), kidney diseases (such as glomerular diseases), and epilepsy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Manidipine-d4 | Manidipine-d4 is the deuterium labeled Manidipine (HY-B0419). Manidipine is an orally active calcium channel antagonist. Manidipine regulates the expression of cytokines (IL-1β, IL-6). Manidipine has a hypotensive effect. Manidipine can be used in the study of cardiovascular diseases (such as hypertension, myocardial ischemia-reperfusion injury, ventricular hypertrophy), kidney diseases (such as glomerular diseases), and epilepsy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Roth M, et al. Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci U S A. 1992 May 1;89(9):4071-5. [Content Brief]
- [2]. Huang S, et al. Manidipine inhibits endothelin-1-induced [Ca2+]i signaling but potentiates endothelin's effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cells. Am Heart J. 1993 Feb;125(2 Pt 2):589-97. [Content Brief]
- [3]. Costa S, et al. Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages. Pharmacol Res. 2010 Sep;62(3):265-70. [Content Brief]
- [4]. Yoshiyama M, et al. Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricular hypertrophy. Jpn Circ J. 1998 Jan;62(1):47-52. [Content Brief]
- [5]. Tojo A, et al. Effects of manidipine hydrochloride on the renal microcirculation in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1992 Dec;20(6):895-9. [Content Brief]
- [6]. Rossoni G, et al. Combined simvastatin-manidipine protect against ischemia-reperfusion injury in isolated hearts from normocholesterolemic rats. Eur J Pharmacol. 2008 Jun 10;587(1-3):224-30. [Content Brief]
- [7]. Haraguchi K, et al. Catalepsy induced by manidipine, a calcium channel blocker, in mice. J Pharm Pharmacol. 1996 Apr;48(4):429-32. [Content Brief]
- [8]. Souza C N S, et al. 074—(SOA0068) Anticonvulsant activity of acute treatment with manidipine in pentylenetetrazole-and pilocarpine-induced seizure models in mice. Epilepsy & Behavior, 2014, 38: 214.
